Openbookopenbook
Equity
Abcellera BiologicsĀ Inc(ABCL)
USD --+0.00%
Reward36Moderate
Risk46Moderate
šŸ“Š75%Data
Thin -195% profit margin Ā· Revenue growing 788% YoY
ABCL
+0.0 Ā· +0.00%
USD Ā· NASDAQ
Abcellera BiologicsĀ Inc | Healthcare
Structurally Challenged
Market Cap:1.54Bn
ā„¹ļø
Reward Rating
36
Moderate
Bottom 5% (model universe)
75% data coverage
ā„¹ļø
Risk Rating
46
Moderate
Risk Assessment
ā„¹ļø

Educational tool only ā€“ Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ā„¹ļø Educational tool only Ā· More
Limited data coverage
We don't have enough public data on ABCL to score it reliably yet ā€” Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock ā€” scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have ā€” try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $9.14.

What is Abcellera BiologicsĀ Inc?

engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

ABCL Ā· Verdict

Limited reward Ā· moderate risk

ABCL's standout is balance sheet; cash flow and growth weigh on the picture.

Based on 88% data coverage

ABCL Ā· Verdict

Whatā€™s working & what to watch

Strengths 1

  • Balance sheet86/100

    Current ratio 11.32

Watchouts 4

  • Cash flow20/100

    -232% free-cash-flow margin

  • Growth28/100

    Revenue -46.3% CAGR

  • Profitability32/100

    -195% net margin Ā· -14% ROE

  • Valuation43/100

    P/E 27.5Ɨ

Model-based scoring. For information only ā€” not financial advice.

What is Abcellera BiologicsĀ Inc?

engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.54B.

Financial Highlights

Investment Breakdown

šŸ“ˆ Growth
Revenue and earnings growing steadily, indicating improving operating performance.
šŸ’° Profitability
Thin or inconsistent margins weigh on earnings quality.
āš ļø Risk
Risk profile appears balanced versus broad market conditions.
šŸ’ø Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (36)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.54B
P/E RatioN/A
Dividend YieldN/A
52 Week High6.515
52 Week Low1.94
Last AnnualDecember
IPO Date12/11/2020
IncorporatedUSA
Shares Outstanding305M
No. of Employees562
IndustryBiotechnology
ExchangeNASDAQ
Beta1.027
CurrencyUSD
Websitewww.abcellera.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

Ā© 2026 Openbook Analytics Ltd Ā· Company No.Ā SC843579 Ā· Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.